Eli Lilly and Company (NYSE:LLY) Shares Climb 3.1% Following Better-Than-Expected Earnings

Eli Lilly and Company (NYSE:LLY) shares traded up 3.1% during trading on Friday following a better than expected earnings announcement. The stock traded as high as $1,449.68 and last traded at $1,415.64. Approximately 5,030,224 shares traded hands during mid-day trading, an increase of 71% from the average session volume of 2,942,995 shares. The stock had previously closed at $1,373.70.

The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.68 by $1.80. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The firm had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. During the same period last year, the business earned $7.02 earnings per share. The business’s revenue was up 38.6% on a year-over-year basis.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is 23.22%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong quarterly results: Third-quarter revenue rose 39% year over year to $24.4 billion, while adjusted EPS of $7.48 significantly exceeded analysts’ expectations. Mounjaro sales climbed 65% to $10.7 billion and Zepbound generated $5.35 billion in revenue, demonstrating robust demand for Lilly’s GLP-1 treatments. Lilly reports third-quarter 2026 financial results
• Positive Sentiment: Higher outlook: Lilly raised its 2026 revenue forecast to $91 billion-$92 billion from $85 billion-$87 billion, supported by sustained Mounjaro and Zepbound demand, broader Medicare access and growing middle-income adoption.
• Positive Sentiment: Pipeline support: Positive Phase 3 results for experimental obesity and diabetes drug retatrutide, including performance versus Ozempic, strengthened expectations for Lilly’s next generation of metabolic treatments. Management also pointed to expanding opportunities in oncology, immunology and neuroscience. Eli Lilly retatrutide trial results
• Positive Sentiment: Analyst optimism: Scotiabank, Morgan Stanley and RBC raised their price targets to $1,605, $1,596 and $1,600, respectively, while maintaining positive ratings. These revisions signal confidence that earnings growth can support further appreciation.
• Neutral Sentiment: Valuation and concentration: Lilly’s market capitalization is now comparable to Berkshire Hathaway’s, but roughly two-thirds of revenue is tied to GLP-1 products. The company’s elevated valuation leaves the stock sensitive to any slowdown in obesity-drug growth.
• Negative Sentiment: Pricing and one-time items: Realized prices fell about 15%, although a 53% increase in volume more than offset the decline. Approximately $900 million of quarterly benefits may not recur, while acquisition-related charges pressured reported earnings. Potential employer resistance to covering weight-loss drugs remains an additional risk.

Wall Street Analyst Weigh In

Several brokerages have commented on LLY. Bank of America reiterated a “buy” rating and set a $1,497.00 target price on shares of Eli Lilly and Company in a research note on Friday. Citigroup upped their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Leerink Partners lifted their price target on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 21st. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a report on Thursday, October 15th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $1,413.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,391.29.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. increased its holdings in Eli Lilly and Company by 1.6% in the 2nd quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares in the last quarter. State Street Corp lifted its holdings in Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after purchasing an additional 605,752 shares in the last quarter. Bank of America Corp DE purchased a new position in Eli Lilly and Company during the second quarter valued at approximately $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after purchasing an additional 137,364 shares during the period. Finally, Jennison Associates LLC boosted its position in shares of Eli Lilly and Company by 7.9% in the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock worth $6,550,587,000 after purchasing an additional 400,538 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 3.1%

The stock’s 50 day moving average price is $1,194.34 and its 200-day moving average price is $1,090.89. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $1.33 trillion, a PE ratio of 47.50, a PEG ratio of 1.73 and a beta of 0.46.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.